KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Current Deferred Revenue (2016 - 2025)

Charles River Laboratories International has reported Current Deferred Revenue over the past 17 years, most recently at $210.4 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 15.26% year-over-year to $210.4 million; the TTM value through Dec 2025 reached $210.4 million, down 15.26%, while the annual FY2025 figure was $210.4 million, 15.26% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $210.4 million at Charles River Laboratories International, down from $237.7 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $290.0 million in Q4 2022 and troughed at $210.4 million in Q4 2025.
  • A 5-year average of $245.6 million and a median of $249.4 million in 2024 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: soared 35.75% in 2021 and later fell 15.26% in 2025.
  • Year by year, Current Deferred Revenue stood at $219.7 million in 2021, then skyrocketed by 32.0% to $290.0 million in 2022, then decreased by 5.86% to $273.0 million in 2023, then decreased by 9.04% to $248.3 million in 2024, then fell by 15.26% to $210.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for CRL at $210.4 million in Q4 2025, $237.7 million in Q3 2025, and $268.3 million in Q2 2025.